CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
21.60
0.98%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 21.39
Open 21.14
1-Year Change -11.47%
Day's Range 21.14 - 22.15
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 25, 2024 21.22 0.82 4.02% 20.40 21.53 20.19
Jul 24, 2024 20.36 0.81 4.14% 19.55 20.80 19.55
Jul 23, 2024 19.76 0.77 4.05% 18.99 20.17 18.99
Jul 22, 2024 19.60 0.47 2.46% 19.13 19.77 18.79
Jul 19, 2024 19.11 -0.24 -1.24% 19.35 19.72 19.09
Jul 18, 2024 19.62 -0.12 -0.61% 19.74 19.96 19.40
Jul 17, 2024 19.83 -0.21 -1.05% 20.04 20.68 19.69
Jul 16, 2024 20.38 0.57 2.88% 19.81 20.56 19.61
Jul 15, 2024 19.64 -0.06 -0.30% 19.70 19.89 19.43
Jul 12, 2024 19.67 0.29 1.50% 19.38 20.00 19.29
Jul 11, 2024 19.33 0.44 2.33% 18.89 19.67 18.89
Jul 10, 2024 18.59 0.52 2.88% 18.07 18.59 18.07
Jul 9, 2024 18.37 0.50 2.80% 17.87 18.54 17.61
Jul 8, 2024 18.15 0.28 1.57% 17.87 18.61 17.87
Jul 5, 2024 18.21 -0.26 -1.41% 18.47 18.48 17.90
Jul 3, 2024 18.36 0.19 1.05% 18.17 18.86 17.87
Jul 2, 2024 18.24 -0.58 -3.08% 18.82 18.94 18.15
Jul 1, 2024 19.02 0.54 2.92% 18.48 19.25 18.48
Jun 28, 2024 18.88 -0.28 -1.46% 19.16 19.16 18.49
Jun 27, 2024 19.15 0.12 0.63% 19.03 19.47 19.03

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Xencor Inc Company profile

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Xencor Inc revenues increased from $122.7M to $275.1M. Net income totaled $82.6M vs. loss of $69.3M. Revenues reflect Research collaboration segment increase from $4.5M to $93M, Royalties segment increase from $17.8M to $80.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.21 to $1.42.

Equity composition

Common Stock $0.01 Par, 12/13, 200M auth., 29,422,576 issd., Insiders own approx. 56.73%

Industry: Bio Therapeutic Drugs

465 N. Halstead St.
Suite 200
PASADENA
CALIFORNIA 91107
US

People also watch

XRP/USD

0.61 Price
+1.640% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

67,928.50 Price
+3.990% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,029.00 Price
+1.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,281.07 Price
+4.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading